Thousands of consumers claim pharmaceutical companies and retailers negligently manufactured and stored ranitidine products ...

WASHINGTON, D.C. – The U.S. Food and Drug Administration (FDA) is requesting that manufacturers immediately pull all prescription and over-the-counter (OTC) ranitidine drugs from the market. The ...

The U.S. Court of Appeals for the Eleventh Circuit heard oral arguments on Friday about whether to reverse a 2022 ruling ...

Update 8:55 a.m. EST, Nov 13: The Food and Drug Administration is telling patients and health professionals about two more voluntary recalls of ranitidine. Amneal Pharmaceuticals LLC has recalled ...

Aurobindo Pharma joined a growing list of drugmakers recalling their ranitidine products over concerns they produce a possible carcinogen. Aurobindo is recalling one lot of its 150 mg ranitidine ...

Welcome to Law.com Class Actions: Critical Mass, a weekly briefing for class action and mass tort attorneys.

Another recall has been issued for a generic version of a popular heartburn drug best known as Zantac due to the presence of a potentially cancer-causing impurity. It's the latest in several such ...

On Wednesday, GSK plc (NYSE:GSK) reached agreements with ten plaintiff firms representing approximately 80,000 Zantac product liability cases in the U.S. state courts. These cases account for 93% of ...

All unexpired lots of 150mg and 300mg ranitidine (over-the-counter brand name: Zantac) tablets distributed by by Glenmark Pharmaceutical were recalled late Tuesday for possibly having too much NDMA.

More store brand versions of heartburn medicine ranitidine — name brand version: Zantac — as well as prescription ranitidine got recalled Wednesday by manufacturer Dr. Reddy’s Laboratories. While you ...

The French drug maker Sanofi said Friday it would be voluntarily recalling Zantac in the U.S. and Canada, as the Food and Drug Administration investigates a potentially dangerous contaminant detected ...

GSK GSK1.93%increase; green up pointing triangle shares topped the Stoxx Europe 600 index on Thursday after the pharmaceutical company agreed to pay up to $2.2 billion to settle thousands of U.S.